Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH aims to assess T-DXd in patients with HER2-positive or HER2-low ABC and central nervous system involvement. Methods: This ongoing, five-cohort, phase II study (NCT04420598) enrolled patients with pretreated HER2-positive or HER2-low ABC with stable, untreated, or progressing BMs, and/or leptomeningeal carcinomatosis. Here, we report findings from HER2-positive ABC patients with non-progressing BMs after local therapy (n = 8; cohort 1), asymptomatic untreated BMs (n = 4; cohort 2), or progressing BMs after local therapy (n = 9; cohort 3). Patients received 5.4 mg/kg T-DXd intravenously once every 21 days. The primary endpoint was 16-week progression-free survival (PFS) for cohort 1 and intracranial objective response rate (ORR-IC) for cohorts 2 and 3. Results: As of October 20, 2021, 21 patients received T-DXd. In cohort 1, 16-week PFS rate was 87.5% (95%CI, 47.3-99.7; P < .001). ORR-IC was 50.0% (95%CI, 6.7-93.2) in cohort 2 and 44.4% (95%CI, 13.7-78.8; P < .001) in cohort 3. Overall, the ORR-IC in patients with active BMs was 46.2% (95%CI, 19.2-74.9). Among patients with measurable intracranial or extracranial lesions at baseline, the ORR was 66.7% (12 out of 18 patients; 95%CI, 41.0-86.7), 80.0% (95%CI, 28.4-99.5) in cohort 1, 50.0% (95%CI, 6.7-93.2) in cohort 2, and 66.7% (95%CI, 29.9-92.5) in cohort 3. All responders had partial responses. The most common adverse events included fatigue (52.4%; 4.8% grade ≥3), nausea (42.9%; 0% grade ≥3), neutropenia (28.6%; 19% grade ≥3), and constipation (28.6%; 0% grade ≥3). Two (9.5%) patients suffered grade 1 interstitial lung disease/pneumonitis. Conclusions: T-DXd showed intracranial activity with manageable toxicity and maintained the quality of life in pretreated HER2-positive ABC patients with stable, untreated, or progressing BMs. Further studies are needed to validate these results in larger cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006 · cited 9×
“…response and long-lasting clinical activity of T-DXd in HER2-positive ABC patients; however, both studies excluded patients with active BCBMs. 11,12,14 The antitumor activity of T-DXd appears to be superior to that of tucatinib plus trastuzumab and capecitabine, although no head-to-head…”
BackgroundInfluentialGennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417 · cited 1×
“6,13 DESTINY-Breast01 and DESTINY-Breast03 highlighted the intracranial response and long-lasting clinical activity of T-DXd in HER2-positive ABC patients; however, both studies excluded patients with active BCBMs. 11,12,14 The antitumor activity of T-DXd appears to be superior to that of tucatinib…”
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326 · cited 7×
“4 Until the HER2CLIMB trial, there was limited clinical evidence for systemic management of patients with active BCBMs. 10 HER2CLIMB was the first randomized study to demonstrate an improved antitumor activity in terms of progression-free survival (PFS) and overall survival (OS) of a…”
BackgroundMethodInfluentialSelf-citationTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175 · cited 3×
“12 Based on these results, T-DXd has become the new standard of care in the second-line treatment of patients with HER2-positive ABC.”
BackgroundMethodSelf-citationBachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
Kim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7916 · Cited by 485 · cited 2×
“One of the strengths of DEBBRAH is that it follows the recommendation made by the U.S. Food and Drug Administration, 28 the American Society of Clinical Oncology and Friends of Cancer Research, 29 and the RANO-BM working group 30 to include patients with stable or active BMs in clinical trials, given the high unmet ne…”
BackgroundTreatment strategies for breast cancer brain metastases
Bailleux, C., Eberst, L., & Bachelot, T. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01175-y · Cited by 233 · cited 1×
“Other limitations of the current study comprise its heterogeneous patient population, including patients with a different number of prior lines of therapy and a high proportion of hormone receptor-positive disease in cohorts 1 and 3, its small sample size, and a short follow-up.”
BackgroundSystemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 223
Breast cancer brain metastases: the last frontier
Leone, J. P., & Leone, B. A. (2015) · Experimental Hematology & Oncology · doi:10.1186/s40164-015-0028-8 · Cited by 168 · cited 1×
“20,21 Although efficacy outcomes are more easily measured, subjective symptoms and QoL of patients with BMs are increasingly recognized as a crucial endpoint of cancer care by patients as well as physicians and regulators.”
Background
Cited by
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Bartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider-Schur, S., Starzer, A. M., Forstner, H., Rottenmanner, B., Dieckmann, K., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01935-8 · Cited by 389
Trastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Metadata
- Authors
- Pérez-García, J. M., Vaz Batista, M., Cortez, P., Ruiz-Borrego, M., Cejalvo, J. M., de la Haba-Rodriguez, J., Garrigós, L., Racca, F., Servitja, S., Blanch, S., Gion, M., Nave, M., Fernández-Abad, M., Martinez-Bueno, A., Llombart-Cussac, A., Sampayo-Cordero, M., Malfettone, A., Cortés, J., & Braga, S.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-26
- Volume
- 25
- Issue
- 1
- Pages
- 157-166
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W4281619692
- Cited by
- 246
- References
- 18
- FWCI
- 20.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. https://app.cochat.ai/papers/10.1093/neuonc/noac144
- The paper
- Pérez-García, J. M., Vaz Batista, M., Cortez, P., Ruiz-Borrego, M., Cejalvo, J. M., de la Haba-Rodriguez, J., Garrigós, L., Racca, F., Servitja, S., Blanch, S., Gion, M., Nave, M., Fernández-Abad, M., Martinez-Bueno, A., Llombart-Cussac, A., Sampayo-Cordero, M., Malfettone, A., Cortés, J., & Braga, S. (2023). Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro-Oncology. https://doi.org/10.1093/neuonc/noac144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.